Study to Evaluate Efficacy and Safety of ADVATE in the Treatment of Previously Treated Patients With Hemophilia A
Phase of Trial: Phase IV
Latest Information Update: 26 Oct 2017
Price : $35 *
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Baxalta; Baxter Healthcare Corporation
- 31 Aug 2018 Biomarkers information updated
- 07 Jul 2016 Status changed from active, no longer recruiting to completed.
- 27 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.